Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma or adenocarcinoma of the thoracic esophagus, including the gastroesophageal junction (Siewert type I)~  * Locally advanced disease that is technically operable with curative intent (R0)~ * T3, N0 OR T1-3, N+ OR T4, NX~ * No T1-2, N0~ * No inoperable T4 (unequivocal organ involvement)~ * No distant metastasis, including M1a lymph node status~    * Lymph nodes suspicious of M1a status by CT scan, PET scan, or ultrasound must be verified by fine-needle aspiration cytology~* No carcinoma of the cervical esophagus~* Obstructive tumors allowed~PATIENT CHARACTERISTICS:~Age~* 18 to 70~Performance status~* WHO 0-1~Life expectancy~* Not specified~Hematopoietic~* Neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* AST no greater than 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2.5 times ULN~* Bilirubin no greater than 1.5 times ULN~Renal~* Creatinine clearance greater than 60 mL/min~Cardiovascular~* No New York Heart Association class III or IV congestive heart failure~* No unstable angina pectoris~* No myocardial infarction within the past 3 months~* No significant arrhythmias~* No other severe or uncontrolled cardiovascular disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 12 months after study treatment~* No definite contraindications to corticosteroids as premedication~* No geographic situation that would preclude proper staging and follow-up~* No active uncontrolled infection~* No preexisting peripheral neuropathy greater than grade 1~* No uncontrolled diabetes mellitus~* No active autoimmune disease~* No other serious medical condition that would preclude study participation~* No other prior or concurrent malignancy except nonmelanoma skin cancer or adequately treated carcinoma in situ of the cervix~* No significant neurologic or psychiatric disorder, including psychotic disorders, dementia, or seizures that would preclude comprehension and ability to provide informed consent and complete quality of life questionnaires~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy to the chest~Surgery~* Not specified~Other~* More than 30 days since prior treatment on another clinical trial~* No other concurrent experimental drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Docetaxel and Cisplatin chemo- and radiochemotherapy followed by surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).